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Abstract
Background: Monoclonal antibodies (mAbs) and their derivatives have become one of the most important classes
of therapeutic drugs. Their multiple applications increased the interest for understanding their complex structure. In
vivo, animal cells are able to fold mAbs correctly (Song et al, J Biosci Bioeng 110:135-40, 2010), whereas previous
in vitro approaches were scarce and mostly unsuccessful.
Results: In this work, we compared in vitro assembly characteristics of trastuzumab, produced either by A) physical
separation and refolding of its sub-units or B) direct joining of individually produced heavy and light chains. Native
and denatured structures of trastuzumab were determined by SEC-HPLC, HIC-HPLC and SDS-PAGE.
Conclusions: Our results demonstrate the requirement of correctly folded HC, forming disulfide-bonded dimers, in
order to form a fully functional mAb. Otherwise, the unfolded HC tend to precipitate. We were able to assemble
trastuzumab in this fashion by only mixing them to LC in pH-buffered conditions, while monomeric HC structure
was too unstable to render a functional mAb. This approach has been used in the generation of homogeneous
ADC, with results pending to be published.
Keywords: mAb, Protein structure, Folding, Disulfide bonds, Renaturalization, LC, HC, mAb assembly, Urea, Anti-
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Background
Therapeutic antibodies have risen to prominence over
the past three decades and are the fastest growing drug
class, with currently more than 70 monoclonal anti-
bodies (mAbs) approved by FDA and EMA [1–3]. In
view of the side effects and limitations of mAbs [4] sev-
eral improvements and modifications such as conjugated
mAbs fragments or bispecific antibodies [5, 6] have been
developed [7]. Some of its applications include the treat-
ment of infectious and non-infectious diseases such as
cancer, immune diseases, arthritis and other disorders
resulting from organ transplantation [8].
Mabs in vivo structure
The complex structure of mAbs lead to further efforts in
order to understand their folding, denaturation and
refolding [9, 10]. In vivo, heavy chains (HCs) and light
chains (LCs) are co-translationally translocated into the
endoplasmic reticulum (ER) and folding begins even be-
fore the polypeptide chains are completely translated.
Most immunoglobulins G (IgGs) assemble first as HC
dimers to which LCs are added covalently via a disulfide
bond between the CL and CH1 domains [11]. The Ig
fold is characterized by a greek-key β-barrel topology in
which the barrel is not continuously hydrogen bonded,
but instead composed of two sheets, forming a
sandwich-like structure [11].
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mAbs denaturation and refolding
Pioneering studies on antibody folding were executed on
denatured LCs, allowing in vitro refolding [12]. Cold de-
naturation studies using guanidine hydrochloride were
performed and revealed that mAbs have a potential to
undergo cold denaturation at storage temperatures near −
20 °C (pH 6.3), and this potential needs to be evaluated in-
dependently for individual mAbs [13]. This previous data
shows that it is possible to refold a reversible denatured
mAb without breaking disulfide bonds.
The structure of antibodies and many antibody frag-
ments is composed of multiple domains, often connected
by inter-domain disulfide bonds, which further compli-
cates the already difficult refolding processes.
Refolding of the denatured and reduced immunoglobu-
lins is scarcely successful in vitro [14]. Fab fragments con-
sisting of two subunits have been vigorously employed as
model systems for studying the mechanisms of protein
folding [15, 16], and many refolding technologies have
been used for these fragments, comprising dilution, dialy-
sis, solid phase solvent exchange and size exclusion chro-
matography [16], but several complications are observed
during refolding, which have been overcome. The folding
yield of the denatured and reduced Fab fragment was low
by spontaneous renaturation, but in the presence of a
GroE system (GroEL, GroES and ATP) or protein disul-
phide isomerase (PDI), the folding yield of the denatured
and reduced Fab fragment was higher than that of spon-
taneous renaturation [17]. A similar approach using im-
munoglobulin heavy chain binding protein (BiP) and PDI
was successful in a complete mAb [18].
In vivo and in vitro LC and HC (re)folding
Studies regarding slow dialysis without the assistance
of chaperone were performed to renature a denatured
and reduced IgG at a concentration of 1 mg/ml [19]
with a 70% of folding yield.
In this work, we based our In vitro refolding strategy in this
slow dialysis method but adding a physical separation step by
size exclusion chromatography under denaturing conditions.
The main challenge was the physical chains separation and
their reversible refolding due to the mAb complex structure,
formed by covalent (disulfide) and non-covalent (ionic, hydro-
gen bonds, Van der Waals, hydrophobic) interactions to main-
tain the correct conformation, which is essential to revert the
original mAb structure and functionality.
We studied the feasibility to unfold, physically separate
mAb chains, in vitro correctly refold them and then re-
assemble the original anti-HER2. This assembly ap-
proach is compared with the direct reassembly of the
mAb using in vivo folded chains (independently pro-
duced in HEK293 cultures). The differences between
in vivo and in vitro folded chains are analyzed, as well as
the impact on mAb assembly efficiency.
Results
Unfolding and folding a mAb without physical separation
Firstly, we adapted the Maeda et al. method [20] based on
slow dialysis and appropriate redox buffer in order to test
the ability of the method to refold and reoxidize denatured
and reduced trastuzumab, without physical chain separation.
Results obtained are shown in Fig. 1, where complete
reduction and denaturation of anti-HER2 is achieved in
the conditions discussed (and checked by SDS-PAGE
and SEC-HPLC). After slow dialysis, the antibody is able
to recover its disulfide bonds, showing the same profile
as the initial mAb in SEC-HPLC (results not shown).
Refolded trastuzumab effectively recognizes isolated
HER2 antigen in an ELISA test in the same levels as un-
treated control (Table 1) and binds to protein A affinity
column (Fig. 1), proving that the fragment crystallizable
region (Fc) is also correctly folded. Denatured and re-
duced mAb showed no antigen recognition in the ELISA
test (Table 1).
Unfolding and folding anti-HER with chains physical
separation
Anti-HER2 interchain disulfide bonds were totally re-
duced and mAbs chains were physically separated and
purified by denaturing SEC (Fig. 2a) as described in
methods section (Fig. 8). Protein identity of each peak
was validated through an SDS-PAGE gel (Fig. 2b) and
confirmed the selective chains separation, with little or
none cross-contamination.
After a 5 times volume reduction with a 3KDa Amicon
device, slow dialysis was performed as described before
for HC and LC.
LC structural integrity was first checked by Capto L af-
finity chromatography and no protein could be detected
in the fraction corresponding to flow-through, showing
that reassembled LC could interact with protein L. The
yield from denatured and reduced LC to the folded LC
was 26% (Fig. 3a). The same approach was followed with
HC by using protein A affinity chromatography to check
proper binding. In this case, the fraction corresponding
to the elution peak showed major aggregation in the
non-reduced SDS-PAGE gel (Fig. 3b).
LC and HC were independently buffer-exchanged using
PD Desalting G-25 column to exchange the elution buffer
for 50mM citrate pH 6, in order to recover the original
mAb structure. Under these pH conditions, HC precipi-
tated almost completely and the antigen recognition of
the renatured trastuzumab is reduced to the half com-
pared to the reference mAb (Table 1), indicating that the
mAb structure was not recovered completely.
In vitro and in vivo LC folding structure comparison
LC refolded by slow dialysis (in vitro refolding) under de-
naturing, non-reducing conditions (Fig. 4c LC A) shows a
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single 21 KDa band, corresponding to a monomer struc-
ture. However, under native conditions (Fig. 4a), a molecule
of 42 KDa is detected, indicating that LC is folded forming
dimers without covalent interactions between them
through disulfide bonds.
LC produced by HEK293 (in vivo folding), however, ap-
pears in two forms under denaturing conditions: 55% of 42
KDa band and 45% of 21 KDa band (Fig. 5c LC B). Under
native conditions, 100% of LC is detected as dimers (Fig. 4a).
Hydrophobic differences were also detected: mean-
while in vitro refolded LC shows a single peak in HIC-
HPLC, in vivo folded LC appears as 2 peaks (Fig. 4b).
This result could be related to hydrophobicity differ-
ences between covalently and non-covalently bonded di-
mers, due to the structural differences among them.
LC is not able to recognize HER2 antigen alone (Table 2).
In vitro and in vivo HC folding structure comparison
In vitro refolded HC is mostly appearing as a monomer,
with little dimers forming disulfide bonds, but covalent
aggregation is also observed in SDS-PAGE gel (Fig. 5
HC A).
However, in vivo folded HC is produced forming di-
mers covalently linked by disulfide bonds (Fig. 5 HC B).
When in vitro refolded HC was dialyzed to pH 6, se-
vere precipitation is observed. In vivo folded HC, under
the same conditions, remained soluble.
mAb refolding of independently produced LC and HC
In vivo folded LC and HC were dialyzed with 50mM cit-
rate pH 6 and mixed with a proportion of 5.54 g dcHC /
g LC. Under these conditions, it is possible to recover a
fully functional mAb structure without the need of slow
dialysis or additional chaperones.
The final mAb effectively recognizes isolated
HER2 antigen in an ELISA test in the same levels
as original anti-HER2, while in vivo folded LC or
HC alone do not. The assembled mAb forms a
monomer through non-covalent interactions, but it
was not stabilized through covalent disulfide bonds
because under denaturing conditions only HC di-
mers (100 KDa), LC dimers (42 KDa) and LC
monomers (21 KDa) are detected (Fig. 6b), probably
because interchain thiols are capped with cellular
glutathione and/or cysteine originated during the
cell culture [21]. However, mAb activity has com-
pletely been recovered, as analyzed in the ELISA
test (Table 2). The HC dimers, LC and refolded
mAb identity was confirmed by LC-MS (data not
shown).
Discussion
In this work, we have observed that a denatured and re-
duced mAb analysed by SDS-PAGE and HPLC could be
satisfactory refolded in vitro if HC and LC were not phys-
ically separated. However, if the same protocol was ap-
plied with physical separation of HC and LC followed by
the refolding of each chain independently, HC showed
precipitation and, therefore, the original mAb structure
could not be recovered. In vivo, HC is stabilized through
disulfide bonds, to which LC are added [7, 11]. Here we
hypothesize, that in vitro HC needs LC interaction to gen-
erate dimers and if it appears as a monomer form, HC is
so unstable that smooth pH changes promote its precipi-
tation. It is, therefore, a requisite to have a stable HC
dimer, even if it is only stabilized by non-covalent interac-
tions [22] as in the case of DAR 7–8 Antibody Drug Con-
jugates, to promote mAb assembly.
These observations are supported by results obtained
when HC and LC were independently produced in
HEK293 cultures (in vivo). HC was produced as a cova-
lently bonded dimer and their mixture to dimer LC
allowed obtaining a functional mAb conformation. In
this approach, it has been proved that no HC or LC re-
duction is required to remove glutathione from the
Fig. 1 SDS-PAGE of reduced and refolded anti-HER2. M: molecular
weight marker; i: intact mAb; r/dn: reduced and denatured mAb; dia:
mAb dialyzed by slow dialysis; FT: flow-though of the affinity
chromatography MAb Select SURE; peak: elution peak of the
affinity chromatography
Table 1 Isolated antigen HER2 recognition in the ELISA test to







51 ± 5 AU/
μg
ND 22 ± 1 AU/μg
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capped thiol groups because interactions between LC
and HC are non-covalent. We hypothesize that the anti-
body monomer form is biologically more favorable than
LC dimers, which are so unstable that the reaction is
displaced to bond LC to HC instead of maintaining LC-
LC (even if they are covalently linked). The reduction
and reoxidation of mAbs disulfide bonds have been
studied in detail for manufacturing processes [23, 24]
and it has been demonstrated that after partially redu-
cing the mAb, the original disulfide bonds were re-
formed because the re-oxidized state is favored [25].
However, the current work indicates that the antibody
form is more stable than LC dimers even if the mAb
structure is not stabilized by covalent interactions.
Conclusions
In this work we revealed that HC dimers are imperative for
LC assembly in order to obtain a functional mAb structure
in vitro. If the individual subunits are not correctly or par-
tially folded before mAb reassembly, the functional mAb
cannot be obtained (Fig. 7). Also, the proportion of LC and
HC only affects the yield of the refolding process if a subunit
is added in excess while the protein concentration could
affect the refolding kinetics. Future work will study the
optimization of the mAb refolding process.
Methods
Cell lines and maintenance
Anti-HER2 antibody sequence was obtained by syn-
thetic nucleotide synthesis (GenScript) and cloned in
a tricistronic expression vector derived from the
commercial pIRESpuro3 vector (Clontech) between
NheI-AgeI (LC) BamHI-EcoRI (HC).
HEK293 cells were kindly provided by Dr. A. Kamen
(National Research Council of Canada). HEK293SF-F6
cells were then transfected with the construct and selected
as described previously [26]. The new anti-HER2 antibody
producer cell lines were referred to as HEK293_T10.
HEK293SF-3F6 producing anti-HER2 HC or anti-
HER2 LC were obtained by cloning the synthetic se-
quences in the expression vector pIRESpuro3 (Clontech)
between BamHI and NotI restriction sites for HC and in
the vector pIRESneo3 (Clontech) between NheI and
AgeI sites for LC. HEK293 cells were then transfected
with the different constructs and selected as described
Fig. 2 mAb chains separation with exclusion size chromatography in ÄKTA Avant system under reducing and denaturing conditions. a. UNICORN
Software chromatogram, where absorbance at 280 nm is shaded in blue and absorbance at 260 nm is shaded in red. b. SDS-PAGE gel
corresponding with the isolated peaks collected in the chromatography
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Fig. 3 Gel SDS-PAGE of refolding sequence of LC and HC. a. LC refolding process. M: molecular marker; Sx: Superdex peak of denatured and
reduced LC; Conc: concentrated; Dia: LC diafiltered by slow dialysis; FT: flow-through of Capto L; Peak: Capto L elution peak. b. HC refolding
process. M: molecular marker; i: Superdex peak of denatured and reduced HC; dia: HC diafiltered by slow dialysis; FT: flow-through of MAb Select
SURE; peak: MAb Select SURE elution peak
Fig. 4 LC in vitro and in vivo structure comparison. a. SEC-HPLC of in vitro refolded LC (black) and in vivo folded LC (blue). b. HIC-HPLC of
in vitro refolded LC (black) and in vivo folded LC (blue). c. Gel SDS-PAGE of in vitro refolded LC (black) and in vivo folded LC (blue)
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previously [27]. The new producer cell lines were referred
to as HEK293_THC and HEK293_TLC.
Cells were subcultured at 0.3 × 106 cell/mL three times
per week to keep them in exponential growing phase.
Cell maintenance was performed in 125 mL polycarbon-
ate shake flasks (Corning), with a working volume of 12
mL, and maintained at 37 °C in an incubator with a 5%
CO2 humidity saturated atmosphere (Steri-cult 2000 In-
cubator, Forma Scientific). Flasks were continuously agi-
tated at 110 rpm on an orbital shaking platform (Stuart
SSL110).
Anti-HER2, HC and LC production
Culture media used for HEK293_T10 cell line was
SFM4Transfx-293 (HyClone, SH30382.00) supple-
mented with 4 mM GlutaMAX (Gibco, 35,050,061),
10% (v/v) Cell Boost 5 (60 g/L solution) (HyClone,
SH30865.01), 2% (v/v) Kolliphor P188 (100 g/L solu-
tion) (Sigma, 15,759) and 0.5% (v/v) Antifoam C (10
g/L solution) (Sigma, A6832). Selection pressure was
maintained during the production step by adding
0.2% (v/v) puromycin (1 mg/mL) (Merck, 58,582).
Bioreactor cell cultures were performed using
Flexsafe RM 10 L bags (Sartorius, DFB010L) in a
WAVE 20/50 EHT (GE) with a working volume of
5 L. Temperature was set at 37 °C. Agitation and
angle were set at 22 rpm and 8°, respectively.
Purification of products was performed after 6 days of
culture starting with a clarification step by depth filtra-
tion (Clarisolve 40MS, Merck) followed by bioburden re-
duction filter (Millipore Express SHF, Merck). Clarified
broth was concentrated by tangential flow filtration
(Hydrosart 30 KDa membrane, Sartorius) and then sub-
jected to protein A affinity chromatography (MAb Select
Sure, GE Healthcare) for complete mAb and HC purifi-
cation or protein L for LC purification (Capto L, GE
Healthcare), as described by the supplier. Purified frac-
tions were buffer-exchanged through PD G-25 desalting
columns, (GE). The final buffer was PBS for anti-HER2
and 50mM citrate pH 6 for LC and HC.
MAb denaturation and reduction
In order to obtain reduced and denatured mAbs chains,
affinity purified trastuzumab at 5.75mg/mL was buffer ex-
changed with a PD Desalting G-25 columns equilibrated
with 0,584M Tris-HCl (Roche, 10,708,976,001), and 5.37
mM EDTA (E6758, Sigma), pH 8.6 and then concentrated
5 fold using 30KDa Amicon tubes (Merck). Afterwards,
70mM 2-mercaptoethanol (Bio-rad, 161–0710) and 8M
urea (Panreac, 141,754.1211) were added as described be-
fore [15]. The mixture was incubated for 1 h at 40 °C prior
to the size-exclusion chromatography step.
MAb chains physical separation
Trastuzumab chains were physically separated and puri-
fied by preparative SEC using an ÄKTA AVANT 150
system (GE) equipped with a 500 mL Superdex 200 XK
26/100 column (GE). The column was equilibrated with
0.584M Tris-HCl, 5.37 mM EDTA, 7mM 2-
mercaptoethanol and 8M urea at a flow rate of 3 mL/
min. The column was kept at 4 °C in order to prevent
cyanate formation due to the presence of urea. Peaks
corresponding to trastuzumab HC or LC were separated
and collected using the automated fraction collector. LC
and HC structural integrity was assessed by performing
a run with affinity chromatography, using HiScreen
Capto L column (GE) for LC (binding buffer: sodium
citrate 50 mM (Sigma, S1804), pH 6.5; elution buffer: so-
dium citrate 50 mM, pH = 2.3) and HiScreen Mab Select
Sure (GE) for HC (binding buffer: 20 mM sodium
Fig. 5 HC in vitro and in vivo structure comparison. Gel SDS-PAGE
of in vitro refolded HC (HC A) and in vivo folded HC (HC B)
Table 2 Isolated antigen HER2 recognition in the ELISA test to









ND ND 54 ± 6 AU/μg
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Fig. 6 mAb refolded from independently produced LC and HC. a SEC-HPLC (native structure). The identity of the peaks was checked by LC-MS
(data not shown). b Gel SDS-PAGE (denatured structure)
Fig. 7 Graphical conclusions. Antibody folding is a complex process which occurs in vivo and where light chains are coupled to previously
assembled heavy chain dimers. In this work, denaturation and chains separation of the Trastuzumab antibody followed by their in vitro refolding
through slow dialysis method has shown that heavy chain dimers stabilized by disulphide bridges are necessary in order to reassemble the
whole antibody. Successful in vitro assembly of heavy and light chains has been achieved when the chains have been independently produced
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phosphate, 150mM NaCl, pH 7.4; elution buffer: sodium
citrate 50 mM, pH 3.2).
MAb or chains refolding by slow dialysis
Dialysis buffer: 3.6 mM 2-mercaptoethanol, 1.3 mM re-
duced glutathione (Sigma, G4251) and 1mM EDTA in
0.1M Tris-HCl, pH 8.
Feed initial composition: same as dialysis buffer adding
8M urea.
Slow dialysis was performed by using Slide-A-Lyzer.
Dialysis 3.5KDa (ThermoFisherScientific) device sub-
merged in a 50mL reservoir. The device contained the
test sample plus 1mL 8M urea and 13.6mg glutathione
(Fig. 8), whereas the reservoir was filled with dialysis buf-
fer and 8M urea. Stirred feed bottle contained a constant
volume of 50mL of dialysis buffer, being constantly fed
from dialysis bottle containing 400mL of dialysis buffer.
A 0.25mL/min constant flow rate was maintained dur-
ing a 30 h process using a Schott Iberica peristaltic pump
with 2 heads, during which the reservoir volume is main-
tained constant. Fig. 8 shows a scheme of the system.




Protein mixture composition and relative amount of
each species in the sample was analysed by denaturing,
non-reducing SDS-PAGE (MiniProtean TGX Stain-free
gels 4–20%, Biorad) following by band densitometry
using GelDoc EZ software (Biorad).
SEC-HPLC
SEC analysis was performed in Waters Alliance 2695
(Waters) system using Zenix-C SEC-300 (4.6 × 300mm,
Sepax). The mobile phase was PBS (D1408, Sigma, di-
luted in ultrapure water up to 1x) at a flow rate of 0.35
ml/min. The UV absorbance was measured at a wave-
length of 214 nm.
HIC-HPLC
HIC experiments were performed using a Waters Alli-
ance 2695 system using Proteomix HIC Butyl-NP5
(4.6 × 50mm, Sepax). The mobile phase was a gradient
of 25 mM sodium phosphate pH 7 (S5136 and S5011,
Sigma) with decreasing ammonium sulphate (2170,
Merck) concentration (1.8 M to 0M) and increasing
concentration of isopropanol (AL03151000, Scharlab) to
improve peaks resolution, as recommended by the col-
umn manufacturer, at a flow rate of 0.8 ml/min. The UV
absorbance was measured at a wavelength of 214 nm.
ELISA assay
Antibody assembly was evaluated by comparing in vitro
isolated anti-HER2 recognition with its in vivo assem-
bled variant. Namely, 50 μL of 50 ng/μL HER2 in PBS
solution (10004-HCCH-50, SinoBiological) was placed in
the wells of 96-well Maxisorp plates (ThermoFisher Sci-
entific) for its adsorption at 4 °C overnight. After re-
moval of the supernatants, 100 μL of 2% skim milk
(Oxoid, LP0031) in PBST (PBS plus 0.05% Tween 20
(Sigma, P2287)) were added and allowed to stand at
room temperature for 1 h. The plates were washed three
times with PBST and 50 μL of samples at different dilu-
tions in PBS were placed in each well. After standing at
room temperature for 1 h, the plates were washed three
times with PBST. Then, 50 μL of a solution of 0.1 μg/mL
of policlonal anti-human IgG1 conjugated to Horserad-
ish peroxidase (Genscript, A10254) was added and the
plates were allowed to stand at room temperature for 1
Fig. 8 Slow dialysis scheme. The feed bottle was set in vacuum so the dialysis buffer feeds it at the same speed as the pump 1 feeds the
reservoir. Pump 1 and pump 2 speed is 0,25 mL/min
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h. After three washings with PBST, 50 μL of TMB
(Pierce, 1,854,050) were added. The staining reaction
was carried out at room temperature for 10–15min and
stopped by adding 50 μL of 20% sulfuric acid (Panreac,
141,058.1611) addition. The absorbance at 450–630 nm
was measured with a Labtech LT-4000 microplate
reader (Labtech, MI, USA).
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